康德萊醫械(01501.HK)申請若干內資股"全流通"
格隆匯5月25日丨康德萊醫械(01501.HK)公吿,於2019年11月14日,中國證監會發布了《H股公司境內未上市股份申請"全流通"業務指引》(中國證券監督管理委員會公吿[2019]22號),並配套發佈H股"全流通"申請材料目錄及審核關注要點,全面推開H股"全流通"改革。
根據董事會日期為2021年5月25日的決議,(其中包括)董事會已收到下列股東關於將彼等若干內資股轉換為H股並於聯交所上市的提案:轉換股東已委託及授權公司向中國證監會申請上述58,213,392股內資股"全流通",並進行與申請建議轉換及上市有關的其他事宜。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.